PEG-IFN-α-2b therapy in BCR-ABL-negative myeloproliferative disorders: Final result of a phase 2 study

Cancer

Volumn 110, Issue 9, 2007, Pages 2012-2018

  Jabbour, Elias ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a   Thomas, Deborah ^a   Garcia Manero, Guillermo ^a   Ferrajoli, Alessandra ^a   Faderl, Stefan ^a   Richie, Mary Ann ^a   Beran, Miloslav ^a   Giles, Francis ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCR ABL negative; Essential thrombocythemia; IFN ; Myeloproliferative disorders; Polycythemia vera; Primary myelofibrosis

Indexed keywords

ANAGRELIDE; BCR ABL PROTEIN; HYDROXYUREA; PEGINTERFERON ALPHA2B;

ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPEREOSINOPHILIC SYNDROME; INSOMNIA; MALE; MYALGIA; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SKIN MANIFESTATION; SPLENECTOMY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERFERON ALFA-2B; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; TREATMENT OUTCOME;

EID: 35648966599     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23018     Document Type: Article

References (25)

1. Tefferi A, Barbui T. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc. 2005;80:1220-1232.
2. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006; 107:451-458.
3. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer. 1998;83:1205-1213.
4. Gilbert HS. Persistence of remission of myeloid metaplasia after treatment with recombinant interferon alpha-2b [abstract]. Blood. 1988;72. (Abstract 200a).
5. Gilbert HS. Regression of myeloid metaplasia during IFN-alpha-2b treatment of myeloproliferative disease is accompanied by reduction in circulating concentrations of colony-stimulating factor-1 [abstract]. Clin Res. 1989;37. (Abstract 176).
6. Velu T, Delwiche F. Treatment of essential thrombocythaemia by alpha-interferon. Lancet. 1988;2:628.
7. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res. 2001;21:1103-1115.
8. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 2000;39:10634-10640.
9. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C.The Hepatitis C Intervention Therapy Group. Hepatology. 2000;32:647-653.
10. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs. 2001;61:2263-2288.
11. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs. 2001;15:419-429.
12. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
13. Saba R, Jabbour E, Giles F, et al. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer. 2005;103: 2551-2557.
14. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51:81-86.
15. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005;90:1333-1338.
16. Gugliotta L, Bulgarelli S, Vianelli N, et al. PEG intron treatment in 90 patients with essential thrombocythemia (ET) final report of a phase II study [abstract]. Blood. 2005;106. (Abstract 2600).
17. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106:2397-2405.
18. Michallet M, Maloisel F, Delain M, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia. 2004;18:309-315.
19. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost. 2006;32(4 pt 2):409-416.
20. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037-2040.
21. Kiladjian JJ, Cassinat B, Turlure P, et al. Peg IFNα-2a in polycythemia vera (PV). Results of a phase 2 study by the French "PV-NORD" group [abstract]. Blood. 2006;108. (Abstract 2679).
22. a (PEG-IFN-α-2a; PEGASYS™) for patients with essential thrombocythemia (ET) and polycythemia vera (PV) [abstract]. Blood. 2006;108. (Abstract 4884).
23. Samuelsson J, Mutschler M, Birgegard G, Gram-Hansen R Bjorkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica. 2006;91:1281-1282.
24. Lipton JH, Khoroshko N, Golenkov A, et al. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma. 2007;48:497-505.
25. Comment in: Leuk Lymphoma. 2007;48: 445-446.